These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30582807)

  • 1. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective.
    Garces AE; Stocks MJ
    J Med Chem; 2019 May; 62(10):4815-4850. PubMed ID: 30582807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
    Perry MWD; Abdulai R; Mogemark M; Petersen J; Thomas MJ; Valastro B; Westin Eriksson A
    J Med Chem; 2019 May; 62(10):4783-4814. PubMed ID: 30582813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
    Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors.
    Yang X; Deng M; Zhang X; Wang Y; Song K; Cong R; Meng L; Zhang J
    Chem Biol Drug Des; 2019 Dec; 94(6):2013-2022. PubMed ID: 30381889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
    Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
    Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
    Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
    Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA in cancer: The past 30 years.
    Arafeh R; Samuels Y
    Semin Cancer Biol; 2019 Dec; 59():36-49. PubMed ID: 30742905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoform-Selective PI3K Inhibitors for Various Diseases.
    Bheemanaboina RRY
    Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a new series of PI3K-δ inhibitors from Virtual Screening.
    Fradera X; Deng Q; Achab A; Garcia Y; Kattar SD; McGowan MA; Methot JL; Wilson K; Zhou H; Shaffer L; Goldenblatt P; Tong V; Augustin MA; Altman MD; Lesburg CA; Shah S; Katz JD
    Bioorg Med Chem Lett; 2021 Jun; 42():128046. PubMed ID: 33865969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.
    Dbouk HA; Backer JM
    Trends Pharmacol Sci; 2013 Mar; 34(3):149-53. PubMed ID: 23411347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine: PI3K targeting in advanced breast cancer.
    Rocca A; Melegari E; Palleschi M
    Breast Cancer Res Treat; 2019 Nov; 178(2):479. PubMed ID: 31428907
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
    McPhail JA; Burke JE
    Adv Exp Med Biol; 2020; 1274():203-222. PubMed ID: 32894512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Determinants of Isoform Selectivity in PI3K Inhibitors.
    Miller MS; Thompson PE; Gabelli SB
    Biomolecules; 2019 Feb; 9(3):. PubMed ID: 30813656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.
    Sun P; Meng LH
    Acta Pharmacol Sin; 2020 Nov; 41(11):1395-1402. PubMed ID: 32939035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
    Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
    Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.
    Fournier JCL; Evans JP; Zappacosta F; Thomas DA; Patel VK; White GV; Campos S; Tomkinson NCO
    ACS Chem Biol; 2021 Sep; 16(9):1644-1653. PubMed ID: 34397208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling.
    Maffucci T; Falasca M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent.
    Arcucci S; Ramos-Delgado F; Cayron C; Therville N; Gratacap MP; Basset C; Thibault B; Guillermet-Guibert J
    Biochem J; 2021 Mar; 478(6):1199-1225. PubMed ID: 33740047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
    Rugo HS
    Clin Adv Hematol Oncol; 2019 Sep; 17(9):486-489. PubMed ID: 31549968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.